GlassScriptPhysician profile
Vivek M Mehta
NPI 1114187614
$4,073.18
in general payments reported to CMS, 2019-2025
23 companies · $916 in 2025
The $916 reported for 2025 was more than what 86% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $140 · 2021: $512 · 2022: $445 · 2023: $650 · 2024: $984 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,549.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,063.44 | 2021-2025 | |
| Pfizer INC. | $833.90 | 2023-2025 | |
| Lilly USA, LLC | $429.77 | 2019-2024 | Emgality, Reyvow |
| Abbott Laboratories | $322.13 | 2022-2024 | Eterna |
| Teva Pharmaceuticals USA, INC. | $188.81 | 2019-2025 | Ajovy |
| Si-Bone, INC. | $186.63 | 2024-2025 | |
| Nevro Corp. | $166.06 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $129.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $109.20 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $93.89 | 2021 | |
| Amgen INC. | $86.82 | 2019-2021 | |
| Boston Scientific Corporation | $83.53 | 2019-2025 | Axonics |
| Forte Bio-Pharma LLC | $78.45 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Allergan, INC. | $69.36 | 2019-2021 | |
| Stryker Corporation | $41.42 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $40.27 | 2020 | |
| Collegium Pharmaceutical, INC. | $29.63 | 2023-2024 | Xtampza |
| Bioventus LLC | $26.76 | 2019 | |
| Nalu Medical, INC. | $24.47 | 2024 | Nalu Neurostimulation System |
| Eisai INC. | $20.19 | 2021 | |
| Axsome Therapeutics, INC. | $17.38 | 2025 | Symbravo |
| Vertex Pharmaceuticals Incorporated | $16.42 | 2025 | |
| Merz Pharmaceuticals, LLC | $14.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.